<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526289</url>
  </required_header>
  <id_info>
    <org_study_id>H-16031728</org_study_id>
    <nct_id>NCT03526289</nct_id>
  </id_info>
  <brief_title>GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake</brief_title>
  <acronym>GASOLIN II</acronym>
  <official_title>GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is to evaluate how GIP receptor activation influence food intake
      and mechanisms regulating food intake in obese individuals with type 2 diabetes that are in
      steady treatment with metformin and a GLP-1 receptor agonist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a double blinded cross-over study with two study days: One day of
      GIP infusion (for 5 hours) and one day with placebo (saline) infusion (for 5 hours). The
      primary endpoint is difference in food intake between the two study days. Food intake is
      examined as amount of food eaten during an ad libitum meal.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>food intake</measure>
    <time_frame>time point 300-330 minutes</time_frame>
    <description>food intake (kJ) eaten from an ad libitum meal of pasta bolognese</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appetite</measure>
    <time_frame>time point -30, 0, 30, 60, 90, 120, 150, 180, 210, 240, 270 minutes</time_frame>
    <description>Appetite rated on visual analogue scales (0-10 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>satiety</measure>
    <time_frame>time point -30, 0, 30, 60, 90, 120, 150, 180, 210, 240, 270 minutes</time_frame>
    <description>Satiety rated on visual analogue scales (0-10 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prospective food consumption</measure>
    <time_frame>time point -30, 0, 30, 60, 90, 120, 150, 180, 210, 240, 270 minutes</time_frame>
    <description>prospective food consumption rated on visual analogue scales (0-10 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fullness</measure>
    <time_frame>time point -30, 0, 30, 60, 90, 120, 150, 180, 210, 240, 270 minutes</time_frame>
    <description>fullness rated on visual analogue scales (0-10 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thirst</measure>
    <time_frame>time point -30, 0, 30, 60, 90, 120, 150, 180, 210, 240, 270 minutes</time_frame>
    <description>Thirst rated on visual analogue scales (0-10 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>time point -30, 0, 30, 60, 90, 120, 150, 180, 210, 240, 270 minutes</time_frame>
    <description>Nausea rated on visual analogue scales (0-10 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy expenditure</measure>
    <time_frame>measured at baseline and at time point 250 minutes</time_frame>
    <description>resting energy expenditure measured by indirect calorimetry (kcal/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gastric emptying</measure>
    <time_frame>ingested at time point -15, 0, 60, 75, 90, 105, 120, 150, 180, 210 and 270 minutes</time_frame>
    <description>acetaminophen test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gallbladder emptying</measure>
    <time_frame>at time point -15, 0, 30, 60, 90, 120, 150, 180, 240 minutes</time_frame>
    <description>gallbladder emptying evaluated by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucagon responses</measure>
    <time_frame>at time point -15, 0, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210 and 270 minutes</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin responses</measure>
    <time_frame>at time point -15, 0, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210 and 270 minutes</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide responses</measure>
    <time_frame>at time point -15, 0, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210 and 270 minutes</time_frame>
    <description>blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut hormone responses</measure>
    <time_frame>at time point -15, 0, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210 and 270 minutes</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone turnover markers</measure>
    <time_frame>at time point -15, 0, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210 and 270 minutes</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>GIP infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 hours of continuously GIP1-42 infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 hours of continuously saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GIP1-42 infusion</intervention_name>
    <description>5-hour GIP1-42 infusion (time point 0-300 minutes)</description>
    <arm_group_label>GIP infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>5-hour infusion of saline (placebo) (time point 0-300 minutes)</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Caucasian men

          -  Age between 18 and 70 years

          -  Body mass index (BMI) between 25 and 40 kg/m2

          -  Type 2 diabetes (diagnosed according to the criteria of the World Health Organization)
             with HbA1c &lt;69 mM (&lt;8.5 %)

          -  In stable treatment for ≥3 months with metformin ≥1 g and a GLP-1 receptor agonist.

          -  Informed consent

        Exclusion criteria

          -  Anaemia (haemoglobin outside normal range)

          -  Any current or prior gastrointestinal disease that may interfere with the endpoint
             variables

          -  Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase
             (ASAT) &gt; 2 times normal values) or history of hepatobiliary disorder.

          -  Nephropathy (serum creatinine above normal range and/or albuminuria).

          -  Anorexia, bulimia or binge eating disorder

          -  Allergy or intolerance to ingredients included in the standardised meals

          -  Tobacco smoking

          -  Treatment with other glucose lowering drugs than GLP-1 receptor agonists and
             metformin.

          -  Any regular drug treatment (besides metformin and GLP-1 receptor agonists) that cannot
             be discontinued for a minimum of 12 hours

          -  Any physical or psychological condition that the investigator feels would interfere
             with trial participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>male fænotype</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Filip Knop, MD, PhD</last_name>
    <phone>004538674266</phone>
    <email>filip.krag.knop.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natasha Bergmann, MD</last_name>
    <phone>004538677514</phone>
    <email>natasha.chidekel.bergmann@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for diabetes research</name>
      <address>
        <city>Hellerup</city>
        <zip>DK-2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Bergmann, MD</last_name>
      <phone>38677514</phone>
      <email>natasha.chidekel.bergmann@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Natasha Chidekel Bergmann</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

